Crizotinib

Overview

Crizotinib is an oral tyrosine kinase inhibitor that targets the anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1), and is primarily used for the treatment of non-small cell lung cancer (NSCLC). It is designed to block the growth of cancer cells by inhibiting the action of the kinases involved in their proliferation.

Patent & exclusivity (US)

Per the FDA Orange Book (5 approved US products), the latest listed US patent on Crizotinib expires 6 Nov 2029 and exclusivity 13 Jul 2029. Generic API sourcing typically opens up once these lapse.

Therapeutic areas